Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer

about

Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer

Item

http://www.wikidata.org/entity/Q57110662

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2018

@uk

name

Clinical Potential of Human Ep ...... tor 3 Imaging in Breast Cancer

@en

Clinical Potential of Human Ep ...... tor 3 Imaging in Breast Cancer

@nl

type

Item

label

Clinical Potential of Human Ep ...... tor 3 Imaging in Breast Cancer

@en

Clinical Potential of Human Ep ...... tor 3 Imaging in Breast Cancer

@nl

prefLabel

Clinical Potential of Human Ep ...... tor 3 Imaging in Breast Cancer

@en

Clinical Potential of Human Ep ...... tor 3 Imaging in Breast Cancer

@nl

P1476

Clinical Potential of Human Ep ...... tor 3 Imaging in Breast Cancer

@en

P2093

Gary A Ulaner

http://www.w3.org/2001/XMLSchema#string

Jason S Lewis

http://www.w3.org/2001/XMLSchema#string

Kelly E Henry

http://www.w3.org/2001/XMLSchema#string

P2860

Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography

Positron Emission Tomography in Breast Cancer

Molecular Imaging of Biomarkers in Breast Cancer

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

Trastuzumab--mechanism of action and use in clinical practice

Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.

Development of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer.

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer

P304

423-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CPET.2018.02.010

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30100080

http://www.w3.org/2001/XMLSchema#string

P932

6092024

http://www.w3.org/2001/XMLSchema#string